107 related articles for article (PubMed ID: 33882487)
1. Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations.
Farshadpour F; Taherkhani R
Med Princ Pract; 2021; 30(5):422-429. PubMed ID: 33882487
[TBL] [Abstract][Full Text] [Related]
2. Age-Related Differences in Immunological Responses to SARS-CoV-2.
Wong LSY; Loo EXL; Kang AYH; Lau HX; Tambyah PA; Tham EH
J Allergy Clin Immunol Pract; 2020; 8(10):3251-3258. PubMed ID: 32861856
[TBL] [Abstract][Full Text] [Related]
3. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.
Fierz W; Walz B
Front Immunol; 2020; 11():1120. PubMed ID: 32582200
[TBL] [Abstract][Full Text] [Related]
4. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
[TBL] [Abstract][Full Text] [Related]
5. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
6. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
Front Immunol; 2020; 11():1880. PubMed ID: 32973779
[TBL] [Abstract][Full Text] [Related]
7. Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms.
Jafarzadeh A; Jafarzadeh S; Nozari P; Mokhtari P; Nemati M
Scand J Immunol; 2021 Feb; 93(2):e12967. PubMed ID: 32875598
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.
Asrani P; Hassan MI
Mol Cell Biochem; 2021 Feb; 476(2):675-687. PubMed ID: 33064288
[TBL] [Abstract][Full Text] [Related]
9. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
10. Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19.
Kim DM; Kim Y; Seo JW; Lee J; Park U; Ha NY; Koh J; Park H; Lee JW; Ro HJ; Yun NR; Kim DY; Yoon SH; Na YS; Moon DS; Lim SC; Kim CM; Jeon K; Kang JG; Jang NY; Jeong H; Kim J; Cheon S; Sohn KM; Moon JY; Kym S; Han SR; Lee MS; Kim HJ; Park WY; Choi JY; Shin HW; Kim HY; Cho CH; Jeon YK; Kim YS; Cho NH
Cell Rep; 2021 Oct; 37(1):109798. PubMed ID: 34587481
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies mediate virus-immune pathology of COVID-19.
Jacobs JJL
Med Hypotheses; 2020 Oct; 143():109884. PubMed ID: 32512289
[TBL] [Abstract][Full Text] [Related]
12. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.
Fu Y; Cheng Y; Wu Y
Virol Sin; 2020 Jun; 35(3):266-271. PubMed ID: 32125642
[TBL] [Abstract][Full Text] [Related]
13. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
14. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
[TBL] [Abstract][Full Text] [Related]
15. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.
Sánchez-Zuno GA; Matuz-Flores MG; González-Estevez G; Nicoletti F; Turrubiates-Hernández FJ; Mangano K; Muñoz-Valle JF
Int J Immunopathol Pharmacol; 2021; 35():20587384211050199. PubMed ID: 34632844
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation.
Li S; Zhang Y; Guan Z; Li H; Ye M; Chen X; Shen J; Zhou Y; Shi ZL; Zhou P; Peng K
Signal Transduct Target Ther; 2020 Oct; 5(1):235. PubMed ID: 33037188
[TBL] [Abstract][Full Text] [Related]
17. Immunopathogenesis and immunobiology of SARS-CoV-2.
Rabaan AA; Al-Ahmed SH; Al Mutair A; Alhumaid S; Sule AA; Tirupathi R; Fawzy M; Muhammad J; Khan A; Hasan A; Shrestha DB; Sah R; Dhawan M; Tiwari R; Bilal M; Ahmad T; Dhama K
Infez Med; 2021 Jun; 29(2):167-180. PubMed ID: 34061781
[TBL] [Abstract][Full Text] [Related]
18. The Science Underlying COVID-19: Implications for the Cardiovascular System.
Liu PP; Blet A; Smyth D; Li H
Circulation; 2020 Jul; 142(1):68-78. PubMed ID: 32293910
[TBL] [Abstract][Full Text] [Related]
19. Is COVID-19 receiving ADE from other coronaviruses?
Tetro JA
Microbes Infect; 2020 Mar; 22(2):72-73. PubMed ID: 32092539
[TBL] [Abstract][Full Text] [Related]
20. Antibody-dependent enhancement of coronavirus.
Wen J; Cheng Y; Ling R; Dai Y; Huang B; Huang W; Zhang S; Jiang Y
Int J Infect Dis; 2020 Nov; 100():483-489. PubMed ID: 32920233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
